Coherus Oncology (CHRS) Capital Expenditures (2013 - 2025)
Coherus Oncology (CHRS) posted Capital Expenditures of $8.4 million for Q4 2025, up 101.73% sequentially from -$483.4 million in Q2 2025.
Coherus Oncology (CHRS) Capital Expenditures (2013 - 2025) Analysis & Trends
Coherus Oncology has reported Capital Expenditures for 13 years, with the latest figure at $8.4 million in Q4 2025.
- Quarterly Capital Expenditures changed N/A year-over-year to $8.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$470.3 million (down 106.43% YoY) and the FY2025 annual result came in at -$470.3 million, down 106.43% from the prior year.
- Capital Expenditures rose to $8.4 million in Q4 2025 per CHRS's latest filing, from -$483.4 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $8.4 million in Q4 2025 and troughed at -$483.4 million in Q2 2025.
- A 5-year average of -$43.4 million and a median of $206500.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 324.14% in 2022, then plunged 123667.76% in 2024.
- Over 5 years, Capital Expenditures stood at $468000.0 in 2021, then slumped by 81.41% to $87000.0 in 2022, then tumbled by 60.92% to $34000.0 in 2023, then sank by 117747.06% to -$40.0 million in 2024, then jumped by 120.94% to $8.4 million in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $8.4 million, -$483.4 million, and $4.7 million for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.38 Mn |
| Dec 31, 2025 | 8.38 Mn |
| Jun 30, 2025 | -483.40 Mn |
| Jun 30, 2025 | -483.40 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Jun 30, 2024 | -40.00 Mn |
| Jun 30, 2024 | -40.00 Mn |
| Mar 31, 2024 | -187.82 Mn |
| Mar 31, 2024 | -187.82 Mn |
| Dec 31, 2023 | 34,000.00 |
| Dec 31, 2023 | 34,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Dec 31, 2022 | 87,000.00 |
| Dec 31, 2022 | 87,000.00 |
| Sep 30, 2022 | 457,000.00 |
| Sep 30, 2022 | 457,000.00 |